Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 7/20 | 0.50 |
| ▸ | ATP4B known ✓ | P51164 | 7/20 | 0.50 |
| ▸ | BRS3 | P32247 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.50 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.50 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.50 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.50 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.50 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.50 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.50 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.50 |
| ▸ | WDR5 | P61964 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.50 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole SCHEMBL28256110 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL30179968 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1560978 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL29538900 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1560726 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1191 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL21628 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29350786 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29673044 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL23780638 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 630 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | claimed |
| EP-4370128-A1 | TREATMENT OF INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2024-05-22 | — | — | EP | claimed |
| CN-117677387-A | Treatment of inflammatory diseases | 加拉帕戈斯股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-116855463-A | Thioether monooxygenase mutant and application thereof in preparation of chiral azole drugs | 华东理工大学 | 2023-10-10 | — | — | CN | claimed |
| WO-2023285405-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-01-19 | — | — | WO | claimed |
| CN-114524801-A | Method for efficiently producing esomeprazole sodium based on mobile phase | 湖北工程学院 | 2022-05-24 | — | — | CN | claimed |
| US-9422534-B2 | Synthesis of prazole compounds | CODEXIS, INC. (US) | 2016-08-23 | — | — | US | claimed |
| US-20160076008-A1 | SYNTHESIS OF PRAZOLE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-03-17 | — | — | US | claimed |
| EP-2499125-B1 | PROCESS FOR THE RESOLUTION OF OMEPRAZOLE | HETERO RESEARCH FOUNDATION (IN) | 2016-01-27 | — | — | EP | claimed |
| EP-1020461-B2 | Magnesium salt of the (-)-enantiomer of omeprazole and its use | ASTRAZENECA AB (SE) | 2015-10-21 | — | — | EP | claimed |
| WO-2000072838-A1 | NEW USE OF COMPOUNDS AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2000-12-07 | — | — | WO | claimed |
| WO-2000044744-A1 | POTASSIUM SALT OF ($I(S))-OMEPRAZOLE | ASTRAZENECA AB (SE) | 2000-08-03 | — | — | WO | claimed |
| CN-1258217-A | Pharmaceutical formulation of omeprazole | ASTRA AB (SE) | 2000-06-28 | — | — | CN | claimed |
| WO-2000030612-A1 | A METHOD OF PRODUCING DRUG PARTICLES | ASTRAZENECA AB (SE) | 2000-06-02 | — | — | WO | claimed |
| WO-2000028975-A2 | IMPROVED CHEMICAL PROCESS AND PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2000-05-25 | — | — | WO | claimed |
| WO-1999063940-A2 | INHIBITORS OF H+K+-ATPase | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5817338-A | PLASTICIZING COMPOUND TO MINIZE REDUCTION OF ACID RESISTANCE | ASTRA AKTIEBOLAG (SE) | 1998-10-06 | — | — | US | claimed |
| CN-1134666-A | Multiple unit tableted dosage form I | ASTRA AB (SE) | 1996-10-30 | — | — | CN | claimed |
| EP-0723436-A1 | MULTIPLE UNIT TABLETED DOSAGE FORM I | Astra Aktiebolag (SE) | 1996-07-31 | — | — | EP | claimed |
| WO-1996001623-A1 | MULTIPLE UNIT TABLETED DOSAGE FORM I | ASTRA AKTIEBOLAG (SE) | 1996-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | ATP4A 473/4885ATP4B 2764/4885BRS3 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.